莎普爱思(603168.SH):阿奇霉素滴眼液III期临床试验完成首例受试者入组

智通财经
11 Mar

智通财经APP讯,莎普爱思(603168.SH)发布公告,近日,公司组织开展的阿奇霉素滴眼液III期临床试验完成首例受试者入组。

阿奇霉素滴眼液III期临床试验,采用多中心、随机、双盲、安慰剂对照设计,评价阿奇霉素滴眼液在中国化脓性细菌性结膜炎患者中的有效性和安全性,已于2025年3月10日完成首例受试者入组。截至公告披露日,阿奇霉素滴眼液项目累计研发投入约1,449.72万元人民币。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10